1.
Antimicrob Steward Healthc Epidemiol
; 4(1): e90, 2024.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38807931
RESUMO
Levofloxacin prophylaxis reduces bloodstream infections in neutropenic patients with acute myeloid leukemia or relapsed acute lymphoblastic leukemia. A retrospective, longitudinal cohort study compares incidence of bacteremia, multidrug-resistant organisms (MDRO), and Clostridioides difficile (CDI) between time periods of levofloxacin prophylaxis implementation. Benefits were sustained without increasing MDRO or CDI.